Company Overview and News
Harris Corporation (HRS - Free Report) recently announced that as part of the U.S. Army’s two-channel Leader radio indefinite delivery/indefinite quantity (IDIQ) contract, it has secured orders for 1,540 AN/PRC-163 two-channel handheld radios & related equipment and services. The AN/PRC-163 is the most advanced software-defined handheld radio in the world today, providing warfighters and commanders with unprecedented capabilities like enhanced levels of command & control and situational awareness.
RBBN HRS QCOM CLFD
Given South Africa's long-standing requirement for the replacement of the air force's mobile and fixed air defence radars, US-based Harris Corporation (Hangar 3, Stand CE23) this week once again showcased its comprehensive range of capabilities, including radar technologies.
AIRBUS HELICOPTERS has additional order for four H225M multirole utility helicopters from the Royal Thai Air Force, bringing its fleet to 12 units by 2021. NORTHROP GRUMMAN has $22m U.S. Navy contract for Advanced Anti-Radiation Guided Missile (AARGM) full-rate production Lot 7. HARRIS CORP. has $9.7m U.S. Air Force contract for continued space control depot support. LOCKHEED MARTIN delivered 400th Electro-Optical Targeting System for F-35 Lightning II as part of .
LMT NOC HRS
Harris Corporation (HRS - Free Report) along with seven other defense companies and one research organization recently secured a $500 million contract from the U.S. Defense Intelligence Agency (“DIA”) to provide services on the HELIOS project. The 10-year contract has a base period of five years with five additional one-year options. The HELIOS program brings together laser weapon, long-range intelligence, surveillance and reconnaissance and counter-Unmanned Aerial System capabilities to increase situational awareness and layered defense options to combat forces.
RBBN LMT NOC UNP TRNO HRS
Harris Corporation (Hangar 3, Stand CE23) is a leading technology innovator, solving customers' toughest mission-critical challenges by providing solutions that connect, inform and protect. Harris supports government and commercial customers in more than 100 countries. The company is organised into three business segments: Communication Systems, Space and Intelligence Systems and Electronic Systems.
Harris Corporation (HRS - Free Report) along with seven other defense companies and one research organization recently secured a $500 million contract from the U.S. Defense Intelligence Agency (“DIA”) to provide services on the High Energy Laser and Integrated Optical-dazzler with Surveillance system or HELIOS. The 10-year contract has a base period of five years with five additional one-year options.
RBBN LMT NOC HRS
US defence electronics manufacturer Harris Corporation revealed the new president of its Communications Systems business on 12 September. Dana Mehnert will take over from the segment's current president, Chris Young, when he retires at the end of the month.
Harris Corporation (NYSE:HRS) has named Dana Mehnert president of the company’s $1.9 billion Communication Systems business, reporting to Harris Chairman, President and Chief Executive Officer William M. Brown, effective September 30, 2018.
A month has gone by since the last earnings report for Harris (HRS - Free Report) . Shares have added about 0.5% in that time frame, underperforming the S&P 500.
Harris Corporation (HRS - Free Report) recently announced a 20.2% year-over-year hike in its quarterly dividend payout. The proposed dividend of 68.5 cents per share or $2.74 on an annualized basis is payable Sep 21, 2018 to shareholders of record as on Sep 7. Based on the closing price of $164.48 on Aug 27, the proposed dividend affirms a yield of 1.7%. A steady dividend payout is part of the long-term strategy of Harris to provide attractive risk-adjusted returns to its stockholders.
RBBN ECR LMHA HRS QCOM LMHB CLFD LM
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to HRS / Harris Corp. on message board site Silicon Investor.
as of ET